Vicarious Surgical (NYSE:RBOT) Price Target Cut to $8.50 by Analysts at Piper Sandler

Vicarious Surgical (NYSE:RBOT) had its price objective lowered by Piper Sandler from $10.50 to $8.50 in a research report issued on Tuesday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Piper Sandler’s target price suggests a potential downside of 6.55% from the stock’s previous close.

Vicarious Surgical Trading Down 5.5 %

Shares of RBOT traded down $0.53 during mid-day trading on Tuesday, reaching $9.10. The company’s stock had a trading volume of 6,009 shares, compared to its average volume of 32,913. The stock has a market cap of $53.74 million, a P/E ratio of -0.88 and a beta of 1.35. The business has a 50-day simple moving average of $12.70 and a two-hundred day simple moving average of $10.59. Vicarious Surgical has a 1-year low of $4.27 and a 1-year high of $19.00.

Vicarious Surgical (NYSE:RBOT) last released its earnings results on Monday, March 17th. The company reported ($2.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.69) by $0.26. The business had revenue of $2.09 million during the quarter. During the same period in the previous year, the company posted ($2.25) earnings per share. Research analysts anticipate that Vicarious Surgical will post -10.89 EPS for the current year.

Institutional Trading of Vicarious Surgical

Several hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC boosted its stake in shares of Vicarious Surgical by 11.6% during the fourth quarter. Renaissance Technologies LLC now owns 11,534 shares of the company’s stock valued at $152,000 after purchasing an additional 1,200 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Vicarious Surgical by 8.2% in the 4th quarter. Geode Capital Management LLC now owns 30,799 shares of the company’s stock valued at $405,000 after purchasing an additional 2,336 shares during the last quarter. Finally, DnB Asset Management AS grew its position in shares of Vicarious Surgical by 21.1% in the 4th quarter. DnB Asset Management AS now owns 21,213 shares of the company’s stock valued at $279,000 after buying an additional 3,692 shares during the last quarter. Hedge funds and other institutional investors own 47.27% of the company’s stock.

Vicarious Surgical Company Profile

Vicarious Surgical Inc operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc was incorporated in 2014 and is headquartered in Waltham, Massachusetts.